Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers
To Evaluate the Safety & Palliative Treatment Effect on Patients With Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)
Sponsor: Clinical Laserthermia Systems AB
Terminated
Patient recruitment slow
Other terminated trials from Clinical Laserthermia Systems AB
- Neoplasms Pancreatic · Phase NA · Mar 2020
- Malignant Melanoma · Phase NA · May 2019
- Breast Neoplasms · Phase NA · Aug 2018
More terminations from Clinical Laserthermia Systems AB
A NA clinical study on Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Clinical Laserthermia Systems AB and has accumulated 6 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Feb 2019 — Jan 2021 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Jun 2018 — Feb 2019 [monthly]
Recruiting NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Laserthermia Systems AB
For direct contact, visit the study record on ClinicalTrials.gov .